Social media defined as "a conversation supported by online tools," is transforming the way people communicate across the globe. Basically, social media consists of online applications that allow users to generate content, connect with others, and engage in conversation. Many social media sites exist, but healthcare professionals may not know that social media also exists in their realm. It ranges from online medical advice to actual patient-physician appointments. It includes educational banks, public health information dissemination, and online data-platform sharing. Patients use healthcare social media for peer support and empowerment through patient-centered websites.
Web 2.0 is a philosophy associated with online applications that facilitates interactive information sharing, collaboration, while being user-centered. Web 2.0 was adopted by healthcare participants to utilize the core concepts of openness, social networking, participation, collaboration, and apomediation. Apomediation refers to cutting out any middlemen or "gatekeepers" when accessing Internet information and going directly to the information, which is vetted by experts.
"One major concern of healthcare professionals regarding the use of social media in healthcare is that, by nature, it is open and the information is not ‘controllable,’” according to Jeff Cain, EdD, MS, director of education technology at the University of Kentucky College of Pharmacy, Lexington, Ky., who spoke on this topic at the 22nd annual meeting of the Academy of Managed Care Pharmacy in San Diego.
"Many healthcare professionals also use micro-blogging applications such as Twitter to disseminate and receive health-related information and research. By following other healthcare Twitterers, one can quickly be introduced to new publications, stories, and online articles of interest that she or he may not have discovered without extensive searching," said Dr Cain.
Examples of healthcare community sharing sites are PatientsLikeMe, HelloHealth, and Google Health. PatientsLikeMe is a site for patients with similar disease states. Currently there are more than 60,000 users for 19 conditions. Patients communicate about treatments, side effects, and other topics. Patient information is de-identified and aggregated, and can be purchased by pharmaceutical companies and health plans, to be used for research and marketing purposes.
“From the patient perspective, social media has permitted the unprecedented ability for users to socially connect with others who suffer from the same affliction or disease state,” according to Dr Cain. “For those with rare diseases, social networking capabilities of some of the patient community sites allow patients to locate, communicate with, encourage, and support others with similar problems.”
Social networking helpful for patients, but may need to be vetted
Many social media sites exist, but healthcare professionals may not know that social media also exists in their realm. It ranges from online medical advice to actual patient-physician appointments.
Social media defined as "a conversation supported by online tools," is transforming the way people communicate across the globe. Basically, social media consists of online applications that allow users to generate content, connect with others, and engage in conversation. Many social media sites exist, but healthcare professionals may not know that social media also exists in their realm. It ranges from online medical advice to actual patient-physician appointments. It includes educational banks, public health information dissemination, and online data-platform sharing. Patients use healthcare social media for peer support and empowerment through patient-centered websites.
Web 2.0 is a philosophy associated with online applications that facilitates interactive information sharing, collaboration, while being user-centered. Web 2.0 was adopted by healthcare participants to utilize the core concepts of openness, social networking, participation, collaboration, and apomediation. Apomediation refers to cutting out any middlemen or "gatekeepers" when accessing Internet information and going directly to the information, which is vetted by experts.
"One major concern of healthcare professionals regarding the use of social media in healthcare is that, by nature, it is open and the information is not ‘controllable,’” according to Jeff Cain, EdD, MS, director of education technology at the University of Kentucky College of Pharmacy, Lexington, Ky., who spoke on this topic at the 22nd annual meeting of the Academy of Managed Care Pharmacy in San Diego.
"Many healthcare professionals also use micro-blogging applications such as Twitter to disseminate and receive health-related information and research. By following other healthcare Twitterers, one can quickly be introduced to new publications, stories, and online articles of interest that she or he may not have discovered without extensive searching," said Dr Cain.
Examples of healthcare community sharing sites are PatientsLikeMe, HelloHealth, and Google Health. PatientsLikeMe is a site for patients with similar disease states. Currently there are more than 60,000 users for 19 conditions. Patients communicate about treatments, side effects, and other topics. Patient information is de-identified and aggregated, and can be purchased by pharmaceutical companies and health plans, to be used for research and marketing purposes.
“From the patient perspective, social media has permitted the unprecedented ability for users to socially connect with others who suffer from the same affliction or disease state,” according to Dr Cain. “For those with rare diseases, social networking capabilities of some of the patient community sites allow patients to locate, communicate with, encourage, and support others with similar problems.”
FDA Approves Lutathera for Adolescents with Neuroendocrine Tumors
April 23rd 2024Lutathera is a radiotherapeutic that is now approved for patients 12 years and older neuroendocrine tumors in the pancreas or gastrointestinal tract.
FDA Approves Bladder Cancer Immunotherapy
April 23rd 2024ImmunityBio’s Anktiva is an antibody cytokine fusion protein approved to treat patients with non-muscle invasive bladder cancer.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Par Recalls More Treprostinil Due to Silicone in the Product
April 22nd 2024An additional seven lots of Treprostinil are affected on top of last month’s recall of one lot.
FDA Approves Pen Form of Entyvio for Crohn’s Disease
April 19th 2024Entyvio as an injection and subcutaneous formulations is approved to treat both Crohn’s and ulcerative colitis.
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
FDA Approves Lutathera for Adolescents with Neuroendocrine Tumors
April 23rd 2024Lutathera is a radiotherapeutic that is now approved for patients 12 years and older neuroendocrine tumors in the pancreas or gastrointestinal tract.
FDA Approves Bladder Cancer Immunotherapy
April 23rd 2024ImmunityBio’s Anktiva is an antibody cytokine fusion protein approved to treat patients with non-muscle invasive bladder cancer.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Par Recalls More Treprostinil Due to Silicone in the Product
April 22nd 2024An additional seven lots of Treprostinil are affected on top of last month’s recall of one lot.
FDA Approves Pen Form of Entyvio for Crohn’s Disease
April 19th 2024Entyvio as an injection and subcutaneous formulations is approved to treat both Crohn’s and ulcerative colitis.
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.